Bavarian Nordic and the Serum Institute of India (SII) have expanded their strategic partnership by signing an agreement for the production of a chikungunya vaccine (CHIKV VLP).[6] The agreement includes the full transfer of vaccine production technology from Bavarian Nordic to SII to increase capacity for future supplies to low- and middle-income countries.[6] This collaboration replaces the previous agreement with Biological E. Limited.[6] The CHIKV VLP vaccine, marketed as VIMKUNYA, was approved in the US, EU, and UK in 2025 for persons over 12 years of age.[6] The vaccine does not contain viral genetic material, so it is not infectious and cannot cause disease.[6] A regulatory review is underway in Switzerland and Canada.[6] The companies also plan to explore future opportunities for joint development.[6]